FONT-SIZE Plus   Neg

Mylan's Generic Version Of Tricor Tablets For Cholesterol Gets FDA Approval

Generic drug maker Mylan Inc. (MYL), Friday said its unit Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application or ANDA for the generic version of Abbvie Inc.'s (ABBV) cholesterol drug Tricor or Fenofibrate.

Mylan said that its unit Mylan Pharmaceuticals Inc. has shipped Fenofibrate Tablets, 48 mg and 145 mg. The drug is prescribed as an adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, Triglycerides and apolipoprotein B, and to increase high-density lipoprotein cholesterol in adult patients. Fenofibrate Tablets also are indicated for treatment of adult patients with severe hypertriglyceridemia or high blood levels of triglycerides.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Large U.S. companies are holding trillions of dollars overseas in an effort to avoid U.S. taxes, with big-name firms like Apple (AAPL), Pfizer (PFE) and PepsiCo (PEP) named as notable examples. This is the claim made by a pair of non-profit groups, who released a study based on the firms' financial statements. The European Investment Bank or EIB will be examining whether the German auto giant Volkswagen utilized loans from any of the European Union countries to develop the illegal software to evade emissions. If the car maker is a culprit, the Bank will take actions to get back the loan. Mainland reinsurer China Re is set out to reinvigorate the Asian IPO market that went into a lull following the recent market volatility. The reinsurer, which boasts of having 93 percent of the domestic insurers as its clients, is set to list its shares in the Hong Kong market.
comments powered by Disqus
Trade MYL now with 
Follow RTT